We use essential cookies (authentication, your saved goals/stack) by default. With your permission we'll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Prescription medication — not a dietary supplement
Enclomipheneis a prescription (or investigational) drug, not a supplement. It is included here for reference because people research and discuss it (often used off-label) — not as a recommendation. Take it only under a qualified clinician's supervision and only as prescribed; do not source it from grey-market vendors, where identity, purity, and dosing are unverified. The evidence below reflects its clinical trials.
What the evidence says
Most Enclomiphene studies are mechanism or observational rather than RCTs that measure a clinical effect — keep findings provisional.
Most evidence is from mixed-quality randomised trials published 2013–2019 with a typical study size of 15 participants.
Based on 7 studies · 3 RCTs · 75 total participants
Confidence
ModerateBy outcome
Enclomiphene has an evidence score of 4.2/10 — emerging evidence based on 7 indexed studies. The trans-isomer of clomiphene — a selective estrogen receptor modulator (SERM) used off-label/investigationally as a 'fertility-sparing' testosterone therapy. By blocking estrogen feedback at the hypothalamus it raises LH, FSH, and endogenous testosterone while preserving sperm production, unlike exogenous testosterone, which suppresses both. Honest appraisal: Phase-2/3 RCTs show it raises testosterone and keeps sperm counts in the normal range vs topical testosterone — but it is NOT FDA-approved (Androxal failed to gain approval) and is compounded/off-label, and there are NO long-term hard-outcome trials (cardiovascular, bone, mortality). Representative study: PMID 26496621.
The commonly studied dose of Enclomiphene is Investigational / off-label — no FDA-approved dose exists. Trials studied oral enclomiphene citrate at 6.25-25 mg once daily (12.5 mg and 25 mg were the Phase-3 doses). Compounded enclomiphene is used off-label under a clinician at similar doses, but quality and content are not regulated.. Individual needs vary — start at the lower end of the range and adjust based on how you respond.
Testosterone (TRT)
Mostly mechanism / observationalThe primary male androgen and an FDA-approved prescription drug for diagnosed male hypogonadism — and a Schedule III CONTROLLED SUBSTANCE. For men with genuinely low testosterone, randomized trials show real benefits: the Testosterone Trials (TTrials) improved sexual function, mood, anemia and bone density in older hypogonadal men, and the large TRAVERSE trial found TRT non-inferior to placebo for major cardiac events. But those benefits were modest and indication-specific, NOT a longevity or anti-aging result. It is prescription-only; non-medical, supraphysiologic, and 'anti-aging' use is illegal and carries serious harms — erythrocytosis, suppressed sperm production/fertility, cardiovascular and psychiatric risk. This is a harm-reduction reference, not a recommendation, and testosterone is NOT a dietary supplement.
Notable regimens that report including Enclomiphene — documented, not endorsed.
Last reviewed June 2026 · evidence from 7 studies · how we score
This information is for educational purposes only. It is not a substitute for professional medical advice. Always consult a qualified healthcare provider before starting, stopping, or changing any supplement or medication.
Enclomiphene citrate — the trans-isomer of clomiphene (SERM)
The trans-isomer of clomiphene — a selective estrogen receptor modulator (SERM) used off-label/investigationally as a 'fertility-sparing' testosterone therapy. By blocking estrogen feedback at the hypothalamus it raises LH, FSH, and endogenous testosterone while preserving sperm production, unlike exogenous testosterone, which suppresses both. Honest appraisal: Phase-2/3 RCTs show it raises testosterone and keeps sperm counts in the normal range vs topical testosterone — but it is NOT FDA-approved (Androxal failed to gain approval) and is compounded/off-label, and there are NO long-term hard-outcome trials (cardiovascular, bone, mortality).
Phase-2 and Phase-3 randomized trials consistently show enclomiphene raises endogenous testosterone (via increased LH/FSH) while preserving sperm counts in the normal range — unlike topical testosterone, which suppresses spermatogenesis. But it is NOT FDA-approved (Androxal failed to gain approval) and is used compounded/off-label, the trials are short-term and surrogate-endpoint-based, and there are NO long-term hard-outcome data (cardiovascular, bone, mood, mortality), which keeps it emerging.
Enclomiphene citrate is the trans-stereoisomer of clomiphene citrate, a non-steroidal selective estrogen receptor modulator (SERM).
Clomiphene — long FDA-approved for ovulation induction in women and used off-label in men with low testosterone — is a mixture of two isomers: zuclomiphene (cis, long half-life, weakly estrogenic) and enclomiphene (trans, the estrogen-antagonist isomer that drives most of the testosterone-raising effect).
The premise of enclomiphene is to deliver clomiphene's beneficial trans-isomer effect without accumulating the long-lived zuclomiphene.
Mechanistically it blocks estrogen-receptor feedback at the hypothalamus and pituitary, which the brain reads as low estrogen, so it increases pulsatile GnRH and therefore pituitary LH and FSH.
Higher LH stimulates testicular Leydig cells to make more testosterone, and higher FSH supports Sertoli-cell-driven spermatogenesis.
The key clinical contrast is with exogenous testosterone (gels, injections): replacement testosterone raises serum testosterone but suppresses the hypothalamic-pituitary-testicular axis, dropping LH/FSH and impairing sperm production — a problem for men who want to preserve fertility.
Enclomiphene instead 'restores' rather than 'replaces': in Phase-2 and Phase-3 randomized trials (the Repros/Androxal program), oral enclomiphene raised total testosterone into the normal range comparably to topical testosterone, while — unlike the gel — it raised LH and FSH and kept sperm concentrations in the normal range.
That fertility-sparing testosterone effect is the genuine, trial-backed claim and the reason for its strong demand in the TRT community. The honest limits are significant.
Enclomiphene is NOT an approved drug: despite positive Phase-3 testosterone/sperm data, Androxal did not gain FDA approval (the agency's concerns centered on the indication, study endpoints, and estradiol/clinical-benefit questions), so what men actually use today is compounded enclomiphene — variable in quality and dose.
The evidence base is short-term (weeks to a few months) and built around surrogate endpoints (testosterone, LH/FSH, sperm count).
There are NO long-term outcome trials: no data on cardiovascular events, bone mineral density, mood, or mortality over years of use, and SERMs as a class carry plausible concerns (e.g. thromboembolism, visual effects, mood changes with clomiphene).
So the picture is two-sided: a real, randomized, mechanistically-coherent ability to raise testosterone while preserving fertility, against the absence of approval, the reliance on compounded product, and the complete absence of hard-outcome or long-term safety data. This is a hormonal compound, not a longevity agent.
As the trans-isomer of clomiphene, enclomiphene antagonizes estrogen receptors at the hypothalamus and pituitary. The brain reads this as low estrogen and releases the negative feedback that normally restrains GnRH.
Removing estrogen feedback increases pulsatile GnRH, driving the pituitary to secrete more luteinizing hormone (LH) and follicle-stimulating hormone (FSH) — the opposite of what exogenous testosterone does.
Higher LH stimulates testicular Leydig cells to make testosterone; higher FSH supports Sertoli-cell-driven sperm production. The result is restored testosterone while fertility (sperm count) is preserved, rather than replaced.
How Enclomiphene works — from molecular targets to health outcomes. Click an edge to see supporting research.This visualization is in beta — pathways are being refined and expanded.
Tap node to isolate • Pinch to zoom • Tap edge for research
Investigational / off-label — no FDA-approved dose exists. Trials studied oral enclomiphene citrate at 6.25-25 mg once daily (12.5 mg and 25 mg were the Phase-3 doses). Compounded enclomiphene is used off-label under a clinician at similar doses, but quality and content are not regulated.
Can be taken without food
| Form | Type |
|---|---|
| 💊Oral enclomiphene citrate (compounded; investigational — never marketed as an approved drug) | Recommended |
| 💊Clomiphene citrate (the isomer mixture; the more available off-label SERM) | Alternative |
| 💊hCG (maintains intratesticular testosterone/fertility by a different mechanism) | Alternative |
Enclomiphene is the trans-isomer of clomiphene. The approved single-isomer product (Androxal) failed FDA approval, so real-world use is compounded and off-label.
Compare Enclomiphene vs HCG (Human Chorionic Gonadotropin) →Minimum: 6 weeks
Optimal: 16 weeks
Cycling: Not required
Note: Studied as a once-daily oral dose. Dosing is clinician-directed and titrated to testosterone and LH/FSH response, not a fixed supplement schedule.
Dose-response data unavailable. The current published research for Enclomiphene does not provide sufficient dose-specific outcome data to generate reliable dose-response curves.
Refer to the Dosage & Timing section above for recommended dose ranges based on available evidence.
Phase-2/3 RCTs show oral enclomiphene raises total testosterone into the normal range, comparably to topical testosterone, by increasing LH-driven testicular production.
Unlike testosterone gel (which suppresses spermatogenesis), enclomiphene raises FSH/LH and keeps sperm concentration in the normal range — the central fertility-sparing claim.
Androxal (enclomiphene) failed to gain FDA approval; what men use is compounded and off-label, of variable quality and dose, outside a regulated supply chain.
Trials are short-term and measure surrogates (testosterone, LH/FSH, sperm count). There are no cardiovascular, bone, mood, or mortality outcomes over years of use.
This is the main use case the trial data speak to — enclomiphene raises testosterone while keeping sperm counts up. But it is off-label and compounded; discuss with a reproductive endocrinologist or urologist, and consider sperm banking.
Unlikely to help — enclomiphene works by driving an intact pituitary-testis axis; it cannot rescue failed testes.
No long-term cardiovascular or thrombosis outcome data exist; weigh the unknown long-term risk against the lack of approval.
Use is clinician-directed; enclomiphene is a male therapy, but any fertility-related use should be supervised.
Exogenous androgens suppress the hypothalamic-pituitary axis that enclomiphene works through; combining them is contradictory and undermines the fertility-sparing rationale.
Overlapping effects on the estrogen/HPG axis; stacking them is common in TRT circles but is not validated and can produce unpredictable estradiol and lipid effects.
Tip: A known clomiphene-class effect; stop and seek care if vision changes — usually reversible.
Tip: Reported with clomiphene-class SERMs; monitor and discuss with the prescribing clinician.
Tip: Usually transient; were generally comparable to testosterone gel and placebo in the short-term trials.
Tip: A plausible class concern for SERMs; long-term risk in men is not characterized. Seek urgent care for leg swelling, chest pain, or shortness of breath.
Timing is flexible for Enclomiphene — consistent daily use matters more than the time of day. Studied as a once-daily oral dose.
Enclomiphene should be used with caution — talk to a healthcare provider before taking it. The most commonly reported side effects are visual disturbances (blurring, flashes, floaters), mood changes / irritability, headache, hot flashes, nausea. Use caution if any of these apply to you: Primary (testicular) hypogonadism — needs an intact pituitary/testis axis to work; Hormone-sensitive tumors or conditions worsened by raising testosterone/estrogen; History of venous thromboembolism (class concern for SERMs).
Tamoxifen (Nolvadex)
Mostly mechanism / observationalA selective estrogen receptor modulator (SERM) and one of the most successful cancer drugs ever made: in estrogen-receptor-positive breast cancer, five years of adjuvant tamoxifen cuts 15-year recurrence by roughly half and breast-cancer death by about a third (EBCTCG), and it prevents breast cancer in high-risk women (NSABP P-1). Among men it is used OFF-LABEL — it antagonizes estrogen in breast tissue to prevent or treat gynecomastia (well-supported by RCTs during antiandrogen therapy, and in idiopathic/pubertal cases), and it blocks estrogen feedback at the hypothalamus to raise LH/FSH and endogenous testosterone, which is why it appears in male-infertility regimens and bodybuilding post-cycle therapy (PCT). The honest limits are real and non-negotiable: tamoxifen raises the risk of endometrial cancer and venous thromboembolism (clots, pulmonary embolism, stroke) and can cause visual/ocular changes. It is NOT a longevity drug.
Estrogen supplementation works against enclomiphene's mechanism (it blocks estrogen-receptor feedback) and would blunt the testosterone response.